Metabolic impact of anti-angiogenic agents on U87 glioma cells.
BACKGROUND: Glioma cells not only secrete high levels of vascular endothelial growth factor (VEGF) but also express VEGF receptors (VEGFR), supporting the existence of an autocrine loop. The direct impact on glioma cells metabolism of drugs targeting the VEGF pathway, such as Bevacizumab (Bev) or VE...
Main Authors: | Tanja Mesti, Philippe Savarin, Mohamed N Triba, Laurence Le Moyec, Janja Ocvirk, Claire Banissi, Antoine F Carpentier |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4055646?pdf=render |
Similar Items
-
Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
by: Mesti Tanja, et al.
Published: (2018-11-01) -
Malignant gliomas: old and new systemic treatment approaches
by: Mesti Tanja, et al.
Published: (2016-06-01) -
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
by: Mesti Tanja, et al.
Published: (2015-03-01) -
The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
by: Mesti Tanja, et al.
Published: (2023-03-01) -
Hypoxic regulation of the expression of anti-angiogenic genes in U87 glioma cells with loss of function of ern1 signaling enzyme
by: K. I. Kubaichuk, et al.
Published: (2012-12-01)